NeOnc Technologies Holdings, Inc. is a clinical-stage biotech company focused on oncology therapeutics, principally its lead candidate NEO212 targeting brain tumors. Recent FDA feedback on chemistry, manufacturing, and controls (CMC) for NEO212 marks a key regulatory milestone during the complex path to approval. The company’s financial position reveals constrained liquidity and a stretched current ratio, underscoring dependency on continued PIPE financings and partnerships for advancement. Strategic agreements in the MENA region provide regional trial and commercialization pathways, though successful clinical progression and regulatory clearance remain critical uncertainties governing NeOnc’s value creation trajectory.